Center-Authored Papers

Filters: Author is Bellam, Naresh  [Clear All Filters]
Journal Article
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE et al..  2013.  Non-Hodgkin's lymphomas, version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):257-72;quiz273. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L et al..  2012.  Non-Hodgkin's Lymphomas, version 3.2012.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(12):1487-98. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ et al..  2011.  Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.
Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A.  2014.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.. Investigational new drugs. 32(6):1213-25. Abstract